Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25604172 | 0.88 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL25600708 | 0.88 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL25060441 | 0.88 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL23607194 | 0.87 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL22019266 | 0.85 | L3MBTL1 (0.37) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21881780 | 0.78 | L3MBTL1 (0.50) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21881771 | 0.77 | CYP1A1 (0.47) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL22639355 | 0.76 | MEN1 (0.58) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL17403745 | 0.76 | MEN1 (0.58) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL22639317 | 0.76 | MEN1 (0.58) | MEN1KMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4194442-A1 | ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER | Novaled GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3406599-B1 | ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER | NOVALED GMBH (DE) | 2023-02-22 | — | — | EP | disclosed |
| US-20200161559-A1 | Organic Electronic Device Comprising an Organic Semiconductor Layer | NOVALED GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200161559-A1 | Organic Electronic Device Comprising an Organic Semiconductor Layer | C1S, YAP1, ESR1 | MEN1 715/4885KMT2A 2561/4885ALDH1A1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.